Canada - English - Health Canada

taro pharmaceuticals inc - epinephrine - solution - 0.15mg - epinephrine 0.15mg - alpha-and beta-adrenergic agonists

United States - English - NLM (National Library of Medicine)

alvogen inc. - dorzolamide hydrochloride (unii: qzo5366ew7) (dorzolamide - unii:9jdx055tw1) - dorzolamide 22.3 mg in 1 ml

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - dorzolamide hydrochloride (unii: qzo5366ew7) (dorzolamide - unii:9jdx055tw1) - dorzolamide 20 mg in 1 ml

Canada - English - Health Canada

taro pharmaceuticals inc - epinephrine - solution - 0.3mg - epinephrine 0.3mg - alpha-and beta-adrenergic agonists

Canada - English - Health Canada

taro pharmaceuticals inc - epinephrine - solution - 0.15mg - epinephrine 0.15mg - alpha-and beta-adrenergic agonists

Australia - English - Department of Health (Therapeutic Goods Administration)

orion pharma (aus) pty limited - selegiline hydrochloride, quantity: 5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; maize starch; microcrystalline cellulose; mannitol - as an adjunct in the management of late stage parkinson's disease in patients being treated with levodopa and/or a peripheral decarboxylase inhibitor, who exhibit deterioration in the quality of their response to the therapy. indications as approved 22 january 1999 - eldepryl is indicated for the treatment of patients with parkinson's disease. it can be used as monotherapy in the early phases of the disease and as adjunctive therapy with levodopa (with/without a peripheral decarboxylase inhibitor) as an adjunct in the management of late stage parkinson's disease in patients being treated with levodopa and/or a peripheral decarboxylase inhibitor, who exhibit deterioration in the quality of their response to the therapy. indications as approved 22 january 1999 - eldepryl is indicated for the treatment of patients with parkinson's disease. it can be used as monotherapy in the early phases of the disease and as adjunctive therapy with levodopa (with/without a peripheral decarboxylase inhibitor)